Company Filing History:
Years Active: 2024
Title: **Andrew James Carlson: Innovator in Drug Delivery Technology**
Introduction
Andrew James Carlson, based in Thousand Oaks, CA, is an accomplished inventor with a significant contribution to the field of drug delivery devices. With one patent to his name, Carlson's innovation focuses on enhancing the functionality and efficiency of these critical medical devices.
Latest Patents
Carlson's recent patent, titled "Muscle wire escapement activation assembly for a drug delivery device," introduces a novel escapement activation assembly. This assembly comprises a slide featuring multiple pallet engagement portions and a switch engagement portion, along with a pallet that has several slide engagement portions. The mechanism involves a drive connected to the pallet, enabling movement relative to the slide. This arrangement allows for the controlled engagement and disengagement of the slide and pallet, facilitating the operation of the drug delivery device's activation trigger. His innovative work is set to contribute significantly to advancements in medical technology.
Career Highlights
Carlson is currently associated with Amgen Inc., a leading biotechnology company. His role allows him to apply his inventive skills in a sector that is crucial for developing life-saving therapeutics. His work at Amgen Inc. highlights his commitment to improving patient health outcomes through innovative technology.
Collaborations
Throughout his career, Andrew has collaborated with talented professionals such as Sudeshna Dutta Ray and Scott Robert Gibson. These collaborations foster an environment of shared expertise and creativity, enabling them to tackle complex challenges in drug delivery systems.
Conclusion
Andrew James Carlson's innovative approach to drug delivery devices exemplifies the spirit of invention and progression in medical technology. His contributions, particularly through his patent, underscore the importance of continuous innovation in the healthcare sector. As he continues to work with Amgen Inc. and his talented colleagues, the potential for future breakthroughs remains promising.